Summary SARS-CoV-2 has currently precipitated the COVID-19 global health crisis. We developed a medium-throughput drug-screening system and identified a small-molecule library of 34 of 430 protein kinase inhibitors that were capable of inhibiting the SARS-CoV-2 cytopathic effect in human epithelial cells. These drug inhibitors are in various stages of clinical trials. We detected key proteins involved in cellular signaling pathways mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA-damage response that are critical for SARS-CoV-2 infection. A drug-protein interaction-based secondary screen confirmed compounds, such as the ATR kinase inhibitor berzosertib and torin2 with anti-SARS-CoV-2 activity. Berzosertib exhibited potent antiviral activity against SARS-CoV-2 in multiple cell types and blocked replication at the post-entry step. Berzosertib inhibited replication of SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV) as well. Our study highlights key promising kinase inhibitors to constrain coronavirus replication as a host-directed therapy in the treatment of COVID-19 and beyond as well as provides an important mechanism of host-pathogen interactions. Graphical abstract Highlights • Kinase inhibitor screen identified 34 compounds with anti-SARS-CoV-2 activity • Inhibitors targeted mTOR-PI3K-AKT and DNA-damage response (DDR) signaling pathways • ATR kinase inhibitor berzosertib blocked SARS-CoV-1, SARS-CoV-2, and MERS-CoV infection • Treatment with berzosertib blocks SARS-CoV-2 at post-entry level in epithelial cells Garcia et al. screen a library of drug compounds and identify SARS-CoV-2-specific antiviral agents. These drugs have been shown to modulate cellular signaling cascades, including mTOR-PI3K-AKT and DNA-damage response (DDR) pathways. A highly effective drug candidate, berzosertib, blocked multiple coronaviruses, such as SARS-CoV-1, SARS-CoV-2, and MERS-CoV, thus providing a potential therapeutic against COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, high-throughput screen, protein kinase inhibitors, nucleoside analogs, mTOR-PI3K-AKT pathway, DNA-damage response pathway, ATR kinase, berzosertib, 【초록키워드】 Treatment, coronavirus, therapy, SARS-COV-2 infection, clinical trials, drug, antiviral activity, MERS, SARS-CoV-1, MERS-CoV, inhibitors, Health crisis, Replication, Protein, Health, Antiviral agents, therapeutic, kinase inhibitors, Middle East respiratory syndrome Coronavirus, epithelial cells, signaling pathway, respiratory, inhibitor, signaling pathways, Critical, mechanism, protein kinase inhibitors, berzosertib, compounds, cellular, Kinase inhibitor, Cytopathic effect, Anti-SARS-CoV-2 Activity, mTOR, host-pathogen interactions, MAPK, Pathways, Coronavirus replication, Middle East, epithelial cell, protein kinase, cell types, cell type, Abstract, treatment of COVID-19, Compound, Stage, CoV infection, human epithelial cells, library, PI3K, respiratory syndrome coronavirus, drug candidate, MERS-CoV infection, multiple coronaviruses, cellular signaling pathways, signaling cascades, block, effective, highlight, shown, identify, blocked, involved, inhibited, exhibited, provide, modulate, inhibiting, cellular signaling pathway, ATR, DDR, precipitated, protein kinase inhibitor, the SARS-CoV-2, 【제목키워드】 inhibitor, SARS-CoV-2 replication, identify,